Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19

L. Mantovani, Mantovani LT, L T Mantovani, S Miotti, Silvia Miotti, Miotti S, Sylvie Ménard, Ménard S, S Ménard, S Canevari, Canevari S, Silvana Canevari, F Raspagliesi, Francesco Raspagliesi, C. Bottini, Bottini C, F Bottero, Bottero F, Federica Bottero, Colnaghi MI, M. I. Colnaghi
European journal of cancer (Oxford, England : 1990) · 1994 · vol. 30(3) , pp. 363–369 · doi:10.1016/0959-8049(94)90257-7 · PMID:8204360 · W1988368614
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Monoclonal antibodies MOv18 and MOv19 detected folate binding protein in normal tissues and biological fluids from ovarian carcinoma patients, indicating its presence beyond cancerous tissues.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Folate-binding proteins (FBP), which are molecules relevant in folate metabolism, are overexpressed in ovarian carcinomas, as detected by the monoclonal antibodies (MAb) MOv18 and MOv19, which recognise two different epitopes of the gp38/FBP. In this paper, features of the FBP such as the distribution on normal tissues and the release in biological fluids of normal and tumour origin have been investigated. Immunohistochemical analyses on frozen sections of normal tissues showed the presence of the gp38/FBP on some epithelia. The reactivity of both the MAb on Fallopian tubes was intense and comparable to that observed on ovary carcinoma sections. The kidney, bronchial glands, alveolar epithelium of the lung, oesophagus, stomach, pancreas, breast and thyroid showed different levels of staining. By MOv18/MOv19 double-determinant immunoradiometric assay (DDIRMA), the gp38/FBP was found in soluble form in ascitic fluid, serum and urine of nude mice in which the human ovary carcinoma cell line IGROV1 grew as ascitic carcinomatosis. In human biological fluids, the gp38/FBP was detected in ascites of 60% of ovarian carcinoma patients, and in 29% of those with other carcinomas, but not in patients with non-epithelial tumours or with other non-tumoral pathologies. The mean serum arbitrary units (a.u.)/ml values of ovary carcinoma patients were significantly different to those of healthy donors or patients with endometriosis (P < 0.005 and P < 0.01, respectively), but not when compared to the sera of lung carcinoma patients. In addition, the sensitivity of DDIRMA was poor, since only 24% of the ovary carcinoma patients were positive with this assay. When a restricted number of cases selected for the presence of tumour cells in the ascites was examined, the percentage of DDIRMA-positive sera and ascites rose to 41 and 94%, respectively. In the urine, a strong reactivity was observed in the samples of both normal and tumour origin.

My notes (saved in your browser only)

MeSH descriptors

Carrier Proteins Ovarian Neoplasms Receptors, Cell Surface Animals Ascitic Fluid Ascitic Fluid Biomarkers, Tumor Biomarkers, Tumor Carrier Proteins Fallopian Tubes Fallopian Tubes Female Folate Receptors, GPI-Anchored Humans Immunohistochemistry Mice Mice, Nude Ovarian Neoplasms Radioimmunoassay Radioimmunoassay

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (31)

Source provenance

europepmc
last seen: 2026-08-01T06:07:04.264727+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:11:29.222973+00:00
License: CC0 · commercial use OK